Qureight raises $8.5M for clinical trial imaging to accelerate drug development

Qureight targets clinical trial imaging analysis and data curation to look for drug responses and find new endpoints.
Qureight raises $8.5M for clinical trial imaging to accelerate drug development

Biotech company Qureight has today announced the close of their significantly oversubscribed $8.5 million Series A round. 

Founded in 2018 and headquartered in Cambridge, UK, Qureight initially targets clinical trial imaging analysis and data curation in lung and heart disease.

Complex lung and heart diseases, such as Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension, currently have limited treatment options and poor survival rates.

Typically, high-value data from patient scans and records is stored across numerous platforms and databases in an unstructured form. Researchers must manually extract relevant data from sources for their research, a hugely expensive and time-consuming process.

Built to tackle this complex problem, Qureight’s digital infrastructure houses and curates multiple types of medical data for robust analysis.

Qureight has unique healthcare access through data contracts across NHS England and can collect CT scans, biomarkers and other trial endpoints directly from hospitals or clinical research organisations (CROs) in real-time as a complex disease drug trial progresses. This information is securely collated and structured, ready for analysis.

The insights from this analysis can be used to look for drug responses and find new endpoints. The structured data can also be used to build virtual trial patients, making it easier to run AI models and compare disparate data sets.

Ultimately, this allows for the design of more resource-efficient clinical trials, the improvement of existing disease treatments, and the development of powerful new drugs.

 The cloud-based, vendor-agnostic platform is GDPR, HIPPA, and NHS Digital compliant and has ISO13485 accreditation to interrogate clinical trial data.

Qureight has ongoing strategic collaborations and research partnerships with companies such as AstraZeneca, Vicore Pharma, and several NHS Trusts.

Dr Muhunthan Thillai, founder and CEO of Qureight, said:

“The close of our Series A round marks the ‘end of the beginning’ and the start of a new chapter for Qureight as we focus on developing our platform and creating products in new disease areas. 

Our mission to extend the lives of lung and heart disease patients will be bolstered by the invaluable expertise of our new board and new senior team members, and we are looking forward to adding to our strategic biopharma collaborations.”

Hargreave Hale AIM VCT led the round, joined by XTX Ventures, Guinness Ventures, and existing investors, including Playfair Capital, Meltwind, Ascension Life Fund and Cambridge Angels

Lucy Bloomfield, co-manager of the Hargreave Hale AIM VCT, commented:

“Hargreave Hale AIM VCT has a long tradition of investing in innovative, high-growth companies, and the application of AI in life sciences is a particular area of interest.

Through the investment process, the team at Qureight has impressed us with their vision and expertise. We are delighted to be the lead investor in this funding round and look forward to supporting Qureight as the company expands its capability.”

Following the close of this round, new Qureight Board members include:

  •  Dr Debra Barker, an experienced healthcare NED and Chief Medical Officer and previous SVP at Novartis.
  • Jenny Winter, CEO of Animalcare Group and previous VP at AstraZeneca.

Consultant Thoracic Radiologist Dr Simon Walsh joins the Qureight team as their new Chief Scientific Officer. He was previously an NIHR Clinician Scientist at the National Heart and Lung Institute, Imperial College, London, and is the outgoing Imaging Chair at the European Respiratory Society. He is also a member of the Fleischner Society, a prestigious global group of 60 leading respiratory scientists and radiologists.

The funds will accelerate Qureight's AI-driven product portfolio and expand into new diseases, including lung cancer.

Follow the developments in the technology world. What would you like us to deliver to you?
Your subscription registration has been successfully created.